Blog

qordata thought leaders and subject matter experts share their insights and experiences

Written By
zia.qureshi
November 28, 2014
0 Comments

According to a PwC Healthcare Institute report, medical costs are projected to rise by 6.8% in 2015 patients need to be more actively involved in managing their own healthcare today than ever before. This is where the pharmaceutical companies step in and starts actively engaging with patients. Also known as ‘patient activation’ with 60%-70% of premature deaths caused by damaging health activities, it is essential that people engage more with improving their own health.

Pharmaceutical companies have a greater role to play in achieving the objectives of the triple aim framework as mentioned in the Affordable Care Act (ACA); better patient experience, reduced cost of total healthcare and improving clinical trial results. They key role here is of digital health technology through a Patient Engagement Platform (PEP).

Written By
zia.qureshi
November 21, 2014
0 Comments

The EFPIA Transparency Directive is seen as a successor to the US Sunshine ACT also known as PPACA (Patient Protection and Affordable Care Act). The Sunshine Act was first introduced in the US in 2010 with the initial transparency report required by January 2012. The US pharmaceutical organizations embarked upon the PPACA reporting projects as early as 2010 and many programs failed for four primary reasons:

Written By
syed
October 30, 2014
0 Comments

The EFPIA Transparency Directive is seen as a successor to the US Sunshine ACT also known as PPACA (Patient Protection and Affordable Care Act). The Sunshine Act was first introduced in the US in 2010 with the initial transparency report required by January 2012. The US pharmaceutical organizations embarked upon the PPACA reporting projects as early as 2010 and many programs failed for four primary reasons…

Written By
syed
September 23, 2014
0 Comments

The pharmaceutical industry has been one of the most progressive industries of the past decade which has enabled the human gene tremendously, in the ways not imaginable before. It has not only given us larger life spans but the quality of life to spend with. In return it was rewarded with high margins protected by patents and (close to) blind trust by consumers. This lead pharmaceuticals to focus their extravagant marketing and sales budgets on Physicians/Doctors who were the sole contributors to shape the consumers opinion about any treatment. More over the popularly called “Age of Block Busters”, allowed the Pharma to roll in part of their high margin back to discovery of new drugs and another major portion to commercialization of these new discoveries. The landscape for Life Sciences is not that simple and lucrative any more, there are new stakeholders at the consumer’s end, stringent legislation demanding more transparency and the Age of Block Busters coming to an end. Pharma stands today at verge of a paradigm shift; how well it will continue to add value to our lives in future depends on how actively it decides to cope up with these challenges.

Upcoming Event

Life Sciences GDPR Bootcamp

14 Nov to 14 Nov, 2017
10:00 am To 6:00 pm BST
DETAILS

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

Get Answer
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.